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Abstract
Objective
Atherogenic dyslipidemia seems to play a major role in microvascular complications and in
residual microvascular risk after statin therapy, which reduces triglycerides up to 40%. We
assessed whether raised TG levels are associated with an increased burden from micro-
vascular complications in patients with type 2 diabetes.
Methods
Subjects from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicen-
tre Study (n=15,773) were divided in 4 groups depending on whether they had plasma tri-
glycerides below (NTG, 67.8%) or above (HTG, 32.2%) 1.7 mmol/L and were (42.4%) or not
on (57.6%) statin therapy. Estimated GFR (eGFR) was calculated from serum creatinine, al-
buminuria was measured by immunonephelometry or immunoturbidimetry, and retinopathy
was evaluated by fundus examination.
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Results
HTG subjects, either with or without statin, had higher prevalence of albuminuria, reduced
eGFR and chronic kidney disease (CKD), especially the albuminuric forms, but not of reti-
nopathy, than NTG subjects. In contrast, cardiovascular disease and advanced DR were
more prevalent in subjects on statin than in those not, independently of triglyceride levels.
Logistic regression analysis confirmed that HTG, without or with statin, was independently
associated with micro and macroalbuminuria, mildly to severely reduced eGFR, and all
CKD phenotypes, but not with retinopathy. The adjusted odd ratios for CKD increased line-
arly for every 0.26 mmol/L increase (approximately one decile) in triglyceride levels. The in-
crease was higher with increasing severity of albuminuria, eGFR loss and CKD phenotype
as well as in subjects receiving than in those not receiving statin treatment.
Conclusions
Triglycerides are associated with CKD, but not retinopathy in subjects with type 2 diabetes,
independently of statin treatment. These data point to a possible role of hypertriglyceridemia
in the development of CKD, though it remains to be demonstrated that diabetic individuals
might benefit from triglyceride reduction with statins and eventually with combination thera-
py with fibrates.
Trial Registration
www.ClinicalTrials.gov NCT00715481
Introduction
Elevated LDL cholesterol is a major risk factor for cardiovascular disease (CVD), as indicated
by the linear relationship between reduction in LDL cholesterol levels and decrease in CVD
event rates in trials with statins, which inhibit the rate limiting enzyme of cholesterol synthesis
[1]. A recent meta-analysis has shown that statins are as effective in diabetic as in nondiabetic
individuals [2]. Indeed, due to the higher CVD risk associated with diabetes, the absolute re-
duction in CVD risk is higher in diabetic than in nondiabetic patients, though event rates in di-
abetic subjects on statin therapy exceed those of placebo-treated individuals without diabetes
[3]. However, significant residual CVD risk remains after statin treatment, even with intensive
regimens targeting an LDL cholesterol level below 70 mg/dl [4]. This residual risk has been at-
tributed, at least in part, to atherogenic dyslipidaemia, since it is higher in subjects with raised
triglyceride levels [5] and/or low concentrations of HDL cholesterol [6], who benefit from spe-
cific treatments such as fibrates, either alone [7] or in combination with statins [8]. Moreover,
levels of triglycerides [9] and HDL cholesterol [10] are positively and negatively associated, re-
spectively, with CVD risk, independently of LDL cholesterol levels.
Recently, a growing body of evidence has suggested that atherogenic dyslipidaemia might
play a major role also in microvascular complications and contribute to residual microvascular
risk after intensive multifactorial treatment including statin therapy [11]. In fact, the role of
LDL cholesterol in microvascular disease is less clear, as suggested by statin trials showing no
effect on diabetic retinopathy (DR) [12] and modest, if any, impact on chronic kidney disease
(CKD) [13,14]. Conversely, most epidemiological studies found an association of triglycerides
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and, less consistently, HDL-cholesterol with diabetic nephropathy [15,16], whereas contrasting
data exist on the relation between levels of these lipid subfractions and DR [17,18]. In addition,
fenofibrate, either alone or combined with statins, reduced decline in renal function, albumin-
uria, and requirement for laser treatment [19–21], though these effects were not related to im-
provements in triglycerides or HDL-cholesterol levels.
Despite evidence for a major role of atherogenic dyslipidaemia in both macro and microvas-
cular complications and the high prevalence of this abnormal lipid pattern, especially in sub-
jects with type 2 diabetes [22], statin monotherapy is still the most used lipid-lowering
treatment in these individuals [23]. However, statins reduce triglycerides by up to 40%, de-
pending on baseline levels, whereas their effect on HDL cholesterol is less pronounced [24].
This analysis was aimed at assessing whether hypertrygliceridemia, independently of statin
treatment, is associated with an increased burden from microvascular complications in subjects
with type 2 diabetes.
Subjects and Methods
Patients
In this cross-sectional analysis, we used the data collected at the baseline visit for the Renal In-
sufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study using standardized
protocols across study centers [25]. The RIACE Study (registered with ClinicalTrials.gov,
NCT00715481; URL http://clinicaltrials.gov/ct2/show/NCT00715481) is an observational, pro-
spective cohort study on the impact of estimated glomerular filtration rate (eGFR) on morbidi-
ty and mortality from CVD in subjects with type 2 diabetes. Data were collected in a single
database using a dedicated computer software developed by Client-Server.net (Belluno, Italy).
The study was conducted in accordance with the Declaration of Helsinki and the protocol was
approved by the coordinating center’s Ethic Committee (Comitato Etico dell’Azienda Ospeda-
liera Sant’Andrea, Prot. n. 43/2006) and thereafter by the Ethics Committee of each center. Par-
ticipants gave informed consent for participation in the RIACE study, as reported in electronic
records. Consent was either written or verbal, depending on the specific recommendations of
the Ethics Committees, some of which did not request to obtain written consent because (a)
data were anonymized prior to access for this study; (b) only measures required for routine fol-
low-up of diabetic patients were obtained; and (c) no blood or other biological sample was col-
lected from participants for additional measurements.
The RIACE cohort consisted of 15,933 Caucasian patients with type 2 diabetes (defined by
the American Diabetes Association criteria), attending consecutively 19 hospital-based Diabe-
tes Clinics of the National Health Service throughout Italy (see S1 RIACE Investigators) in
years 2007–2008. Exclusion criteria were dialysis or renal transplantation.
The quality and completeness of data were controlled and 160 patients were excluded due
to missing or implausible values; data from the remaining 15,773 patients were
subsequently analyzed.
Measurements
All patients underwent a structured interview in order to collect the following information:
age, smoking status, known diabetes onset and duration, current glucose-, blood pressure
(BP)- and lipid-lowering therapy, with indication of the class of drug. Body weight and height
were assessed and body mass index (BMI) was calculated as weight (kg) / height (m2), then BP
was measured with a sphygmomanometer after a five min of rest with the patients seated with
the arm at the heart level. Hypertension was defined by systolic BP140 mmHg and/or dia-
stolic BP90 and/or anti-hypertensive treatment. Hemoglobin (Hb) A1c was measured by
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high-performance liquid chromatography using DCCT-aligned methods; triglycerides, total
and HDL cholesterol were determined by colorimetric enzymatic methods; LDL cholesterol
was calculated by the Friedwald formula, i.e.: LDL-cholesterol (in mmol/L) = total cholesterol—
[HDL-cholesterol + (triglycerides/2.17)].
The presence of CKD was assessed by measuring albuminuria and serum creatinine. As pre-
viously reported in detail [25,26], albumin excretion rate (AER) was obtained from timed (24
hour) urine collections or calculated from albumin/creatinine ratio in early-morning, first-
voided urine samples, in the absence of symptoms and signs of urinary tract infection or other
interfering clinical conditions. Albuminuria was measured in one-to-three fresh urine samples
for each patient by immunonephelometry or immunoturbidimetry and, in case of multiple
measurements, the geometric mean was used for analysis. In subjects with multiple measure-
ments (4,062 with at least two and 2,310 with three values), concordance rate between the first
value and the geometric mean was>90% for all classes of albuminuria [26]. Patients were then
assigned to one of the following categories of albuminuria (mg/24 hours): normoalbuminuria
(AER<30), microalbuminuria (AER 30–299), or macroalbuminuria (AER300). Serum (and
urine) creatinine was measured by the modified Jaffe method. One to three measurements
were obtained for each patients and eGFR was calculated by the four-variable Modification of
Diet in Renal Disease (MDRD) Study equation [27], using the mean serum creatinine value in
case of multiple measures, as reported in previous publications [25,26]. Patients were then as-
signed to one of the following categories of eGFR (mL/min/1.73 m2): 1 (90); 2 (60–89); 3
(30–59); 4 (15–29); and 5 (<15). Finally, subjects were classified as having no CKD or CKD
Stages 1–5, based on the presence or absence of micro or macroalbuminuria and the value of
eGFR, according to the National Kidney Foundation’s Kidney Disease Outcomes Quality Ini-
tiative [28]. Patients assigned to CKD Stages (and GFR classes) 4 and 5 were pooled together.
As previously reported [25], CKD patients were further classified as having one of the following
CKD phenotypes: albuminuria alone (CKD Stages 1–2), reduced eGFR alone (CKD Stage3
without albuminuria), or both (CKD Stage3 with albuminuria).
In each centre, the presence of DR was assessed by an expert ophthalmologist with dilated
fundoscopy. Patients were classified into the following categories: absent DR, mild, moderate
or severe non-proliferative DR, proliferative DR, or maculopathy, according to the Global Dia-
betic Retinopathy Project Group [29]. Patients were classified based on the actual fundus ap-
pearance or the retinal disease condition which had eventually required a previous
photocoagulation or surgical treatment. For further analysis, patients with non-proliferative
DR of mild or moderate degree were classified as having non-advanced DR, whereas those
with severe non-proliferative DR, proliferative DR, maculopathy, or blindness were grouped
into the advanced, sight-threatening DR category. Subjects with maculopathy and non-ad-
vanced DR were classified as having maculopathy, whereas those with maculopathy and severe
non-proliferative DR or proliferative DR were classified as having one of the latter conditions
[30]. DR grade was assigned based on the worst eye.
Prevalent CVD was assessed from medical history by recording previous documented
major acute CVD events, including myocardial infarction, stroke, foot ulcer or gangrene, am-
putation, coronary, carotid, and lower limb revascularization. CVD events were adjudicated
based on hospital discharge records by an ad hoc committee in each center [31].
Statistical analysis
Since statin treatment influences triglyceride levels, patients were divided in 4 groups depend-
ing on whether they (a) had plasma triglycerides concentrations below or above 1.70 mmol/L
(normal triglycerides [NTG] or high triglycerides [HTG], respectively); and (b) were or were
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not on statin therapy (see S1 Fig). A triglyceride concentration of 1.70 mmol/L represents the
upper level of normal range according to the National Cholesterol Education Program’s Adult
Treatment Panel III recommendations [32].
Data are expressed as median (interquartile range) and/or mean±SD, for continuous vari-
ables, and number of cases and percentage for categorical variables. Continuous variables were
compared by one-way ANOVA, for normally distributed variables, or Kruskall-Wallis test, in
case of variables with a skewed distribution. Pearson 2 was applied to categorical variables. For
post-hoc multiple comparisons, Scheffe’s test, Mann-Whitney U test, and 2 test, 1df were used
for parametric, non-parametric, and categorical variables, respectively.
Binary logistic regression analyses with backward conditional entering of independent vari-
ables (probability for removal>0.10) were then applied. The outcome measures for microvas-
cular complications were albuminuria and eGFR categories or CKD phenotypes for diabetic
nephropathy, and any and advanced retinopathy for DR. In Model 1, the independent variable
was a combination of two dichotomous variables (2x2 factorial combination), i.e. triglyceride
levels (< or1.7 mmol/L) and statin treatment (presence or absence). In Models 2 and 3, the
association of triglycerides below or above the threshold with microvascular complications was
analysed separately in subjects not treated or treated with statins, respectively. The above anal-
yses were repeated with substitution of deciles of triglyceride levels for triglycerides< or
1.7 mmol/L. Covariates for all three models were age, male gender, smoking status, diabetes
duration, HbA1c, BMI, HDL cholesterol, hypertension, and blockade of the renin-angiotensin
system, and, in separate analyses, total or LDL cholesterol. Results of these analyses were ex-
pressed as odd ratios (ORs) with their 95% confidence intervals.
To test how the models fit the data, the Hosmer-Lemeshow test for logistic regression was
applied. Finally, the quadratic regression analysis was employed to assess non-linearity be-
tween TG deciles (expressed as the median value of TG concentration within each decile) and
the corresponding ORs for each microvascular endpoint. The F statistics was run to test wheth-
er addition of the quadratic term improved significantly the model’s ability to explain the vari-
ance of the dependent variable.
All p values were two-sided, and a p value of less than 0.05 was considered statistically sig-
nificant. Statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, Illi-
nois, USA).
Results
Of the 15,773 RIACE participants, 67.8% had triglyceride levels<1.7 mmol/L, whereas the re-
maining 32.2% had values1.7 mmol/L; in addition, 42.4% were on statin treatment, 27.7%
among NTG and 14.7% among HTG subjects (see S1 Fig, S1 Table and S2 Table). Only 396
subjects (2.5%) were on fibrate treatment, 139 NTG and 257 HTG (1.3 vs. 5.1%, P<0.0001).
Patients’ characteristics by triglyceride level and statin treatment
HTG subjects, either with or without statin, had higher HbA1c, BMI, waist circumference,
total, LDL and non-HDL cholesterol, and albuminuria, and lower HDL cholesterol and, only
for subjects on statin, eGFR, as compared with NTG individuals. Patients on statins were older,
less frequently males and current smokers, and more frequently hypertensive and on anti-hy-
pertensive treatment and therapy with blockers of the renin-angiotensin system, as compared
with the corresponding individuals not taking statins (see S1 Table). Moreover, HTG patients,
particularly if on statins, had higher prevalence of CKD, especially the albuminuric forms, than
NTG subjects. In contrast, CVD and advanced DR were more prevalent in subjects on statin
than in those not, independently of triglyceride levels (see S2 Table).
Hypertriglyceridemia and Microvascular Disease
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Hypertriglyceridemia, with or without statin treatment, as an independent
correlate of microvascular outcomes
Logistic regression analyses (Tables 1–3) showed that HTG, with or without statin, was inde-
pendently associated with micro and macroalbuminuria, mildly to severely reduced eGFR, and
all CKD phenotypes, especially Stages 3–5 albuminuric (Model 1). The increase in OR in HTG
vs. NTG was lower in subjects not on statins (Model 2) than in those on statins (Model 3). In
contrast, HTG was not positively associated with any or advanced DR (Table 4). Several covari-
ates entered the models (see Tables 1–4 for Model 1).
When analyses were repeated adding total or LDL cholesterol as covariates, these variables
entered the model only for macroalbuminuria and eGFR<30 ml/min/1.73 m2 (total cholester-
ol) or 60–89 ml/min/1.73 m2 (LDL cholesterol) and the independent association of triglyceride
Table 1. Independent association of triglyceride levels and statin treatment with microalbuminuria andmacroalbuminuria in the RIACE study.*
Microalbuminuria (n = 3,497) Macroalbuminuria (n = 738)
OR 95% CI P OR 95% CI P
Independent variable
Model 1 (TG—statin combination) <0.0001 <0.0001
TG <1.70 mmol/L—no statin 1.0 1.0
TG <1.70 mmol/L—statin 0.869 0.785–0.960 0.006 0.984 0.790–1.225 0.884
TG 1.70 mmol/L—no statin 1.228 1.093–1.378 0.001 1.877 1.492–2.362 <0.0001
TG 1.70 mmol/L—statin 1.191 1.054–1.345 0.005 2.619 2.108–3.255 <0.0001
Model 2 (TGs in not statin users)
TG <1.70 mmol/L 1.0 1.0
TG >1.70 mmol/L 1.210 1.074–1.366 0.002 1.715 1.342–2.192 <0.0001
Model 3 (TGs in statin users)
TG <1.70 mmol/L 1.0 1.0
TG >1.70 mmol/L 1.428 1.255–1.624 <0.0001 2.592 2.060–3.260 <0.0001
Covariates (Model 1)
Age, x year 1.022 1.018–1.027 <0.0001 1.023 1.014–1.033 <0.0001
Male gender 2.008 1.834–2.199 <0.0001 2.594 2.159–3.117 <0.0001
Smoking <0.0001 <0.0001
Never 1.0 1.0
Former 1.111 1.012–1.220 0.028 1.350 1.122–1.624 0.002
Current 1.353 1.206–1.518 <0.0001 1.778 1.422–2.223 <0.0001
Diabetes duration, x year 1.007 1.002–1.011 0.003 1.019 1.010–1.027 <0.0001
HbA1c, x 1% increment 1.163 1.133–1.195 <0.0001 1.159 1.102–1.219 <0.0001
BMI, x 1 unit 1.023 1.014–1.031 <0.0001 1.042 1.025–1.058 <0.0001
HDL cholesterol, x 0.03 mmol/L 0.994 0.991–0.997 <0.0001 —- —- —-
Hypertension 1.314 1.137–1.517 <0.0001 2.419 1.611–3.630 <0.0001
RAS blockade 1.584 1.437–1.745 <0.0001 1.964 1.601–2.410 <0.0001
DR <0.0001 <0.0001
No 1.0 1.0
Non-advanced 1.410 1.254–1.584 <0.0001 1.882 1.512–2.343 <0.0001
Advanced 2.132 1.879–2.420 <0.0001 4.679 3.821–5.729 <0.0001
* Binary logistic regression analysis with backward conditional entering of independent variables.
RIACE = Renal Insufficiency And Cardiovascular Events; OR = odd ratio; CI = confidence interval; TG = triglyceride; RAS = renin-angiotensin system;
DR = diabetic retinopathy.
doi:10.1371/journal.pone.0125512.t001
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levels and statin treatment with microvascular complications was not influenced (data not
shown). Also exclusion of subjects on fibrate therapy did not affects results (data not shown).
The Hosmer-Lemeshow test was significant only for eGFR 60–89 ml/min/1.73 m2 in Model 1
(χ2 = 17.638; 8 df, p = 0.024) and 2 (χ2 = 25.656; 8 df, p = 0.001), and for any DR, again in
Model 1 (χ2 = 40.501; 8 df, p<0.001) and 2 (χ2 = 55.057, 8 df, p<0.001).
Relation of triglyceride levels with microvascular disease
The OR for all measures of CKD (Table 5), but not for any or advanced DR (not shown), ad-
justed for several variables including LDL cholesterol, increased for every 0.26 mmol/L increase
(approximately one decile) in triglyceride levels. The increase in OR was higher with increasing
Table 3. Role of triglyceride levels & statin treatment as covariates of CKD phenotypes in the RIACE study. *
CKD Stages 1–2 (n = 2,949) CKD Stages 3 non albuminuric
(n = 1,673)
CKD Stages 3 albuminuric
(n = 1,286)
OR 95% CI p OR 95% CI p OR 95% CI p
Independent variable
Model 1 (TG—statin combination) <0.0001 <0.0001 <0.0001
TG <1.70 mmol/L—no statin 1.0 1.0 1.0
TG <1.70 mmol/L—statin 0.875 0.784–0.976 0.016 1.182 1.027–1.361 0.020 1.033 0.870–1.226 0.710
TG 1.70 mmol/L—no statin 1.227 1.081–1.393 0.002 1.535 1.294–1.820 <0.0001 2.003 1.654–2.427 <0.0001
TG 1.70 mmol/L—statin 1.246 1.090–1.426 0.001 1.838 1.553–2.175 <0.0001 2.667 2.213–3.214 <0.0001
Model 2
TG <1.70 mmol/L 1.0 1.0 1.0
TG >1.70 mmol/L 1.205 1.058–1.373 0.005 1.499 1.259–1.786 <0.0001 1.960 1.606–2.392 <0.0001
Model 3
TG <1.70 mmol/L 1.0 1.0 1.0
TG >1.70 mmol/L 1.452 1.259–1.675 <0.0001 1.559 1.304–1.864 <0.0001 2.631 2.151–3.219 <0.0001
Covariates (Model 1)
Age, x year 1.019 1.014–1.024 <0.0001 1.101 1.093–1.109 <0.0001 1.095 1.086–1.105 <0.0001
Male gender 2.067 1.868–2.288 <0.0001 0.469 0.416–0.530 <0.0001 1.373 1.186–1.589 <0.0001
Smoking <0.0001 —- —- —- 0.001
Never 1.0 1.0
Former 1.107 0.999–1.227 0.052 1.300 1.118–1.510 0.001
Current 1.429 1.266–1.613 <0.0001 1.263 1.031–1.548 0.024
Diabetes duration, x year 1.006 1.001–1.011 0.016 1.007 1.002–1.013 0.011 1.020 1.013–1.027 <0.0001
HbA1c, x 1% increment 1.197 1.162–1.232 <0.0001 —- —- —- 1.108 1.061–1.157 <0.0001
BMI, x 1 unit 1.031 1.022–1.040 <0.0001 1.026 1.015–1.038 <0.0001 1.030 1.016–1.044 <0.0001
HDL cholesterol, x 0.03 mmol/L 0.995 0.992–0.999 0.009 0.984 0.979–0.988 <0.0001 0.982 0.977–0.988 <0.0001
Hypertension 1.367 1.173–1.592 <0.0001 1.367 1.096–1.706 0.006 1.634 1.213–2.201 0.001
RAS blockade 1.652 1.487–1.835 <0.0001 1.466 1.283–1.675 <0.0001 2.128 1.807–2.506 <0.0001
DR <0.0001 <0.0001 <0.0001
No 1.0 1.0 1.0
Non-advanced 1.348 1.184–1.535 <0.0001 1.096 0.919–1.306 0.308 1.925 1.613–2.297 <0.0001
Advanced 2.256 1.960–2.596 <0.0001 1.462 1.200–1.780 <0.0001 4.110 3.429–4.927 <0.0001
* Binary logistic regression analysis with backward conditional entering of independent variables.
RIACE = Renal Insufficiency And Cardiovascular Events; CKD = chronic kidney disease; OR = odd ratio; CI = confidence interval; TG = triglyceride;
RAS = renin-angiotensin system; DR = diabetic retinopathy.
doi:10.1371/journal.pone.0125512.t003
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severity of albuminuria, eGFR loss and CKD phenotype as well as in subjects on statin treat-
ment than in those not treated with these agents. Risk for CKD increased with deciles of triglyc-
eride levels. In subjects not on statin therapy, excess risk was significant for triglyceride
values> 2.05 mmol/L, for CKD Stages 1–2 and CKD Stages3 nonalbuminuric, and>1.05
mmol, for CKD Stages3 albuminuric. In contrast, in subjects on statin therapy, the threshold
was very low (>0,74 mmol/L) for all CKD phenotypes (Fig 1). Increases were linear, since
Table 4. Independent association of triglyceride levels and statin treatment with any and advanced DR in the RIACE study. *
Any DR (n = 3,497) Advanced DR (n = 1,540)
OR 95% CI P OR 95% CI P
Independent variable
Model 1 (TG—statin combination) 0.001 0.015
TG <1.70 mmol/L—no statin 1.0 1.0
TG <1.70 mmol/L—statin 1.049 0.949–1.159 0.348 1.081 0.939–1.244 0.279
TG 1.70 mmol/L—no statin 0.805 0.712–0.910 0.001 0.807 0.679–0.958 0.014
TG 1.70 mmol/L—statin 0.932 0.822–1.056 0.269 1.004 0.846–1.191 0.966
Model 2 (TGs in not statin users)
TG 1.70 mmol/L 1.0 1.0
TG >1.70 mmol/L 0.835 0.738–0.944 0.004 0.857 0.721–1.018 0.080
Model 3 (TGs in statin users)
TG 1.70 mmol/L 1.0 1.0
TG >1.70 mmol/L 0.853 0.745–0.976 0.021 0.894 0.744–1.073 0.227
Covariates (Model 1)
Age, x year 0.983 0.978–0.988 <0.0001 0.970 0.963–0.976 <0.0001
Male gender 1.079 0.987–1.180 0.093 —- —- —-
Smoking 0.094 0.001
Never 1.0 1.0
Former 0.910 0.826–1.004 0.059 0.839 0.736–0.957 0.009
Current 0.906 0.802–1.024 0113 0.761 0.639–0.905 0.002
Diabetes duration, x year 1.067 1.063–1.072 <0.0001 1.067 1.060–1.073 <0.0001
HbA1c, x 1% increment 1.206 1.175–1.239 <0.0001 1.179 1.138–1.221 <0.0001
BMI, x 1 unit 1.010 1.002–1.019 0.014 1.011 1.000–1.022 0.051
HDL cholesterol, x 0.03mmol/L —- —- —- —- —- —-
Hypertension —- —- —- 1.200 0.968–1.487 0.096
RAS blockade 1.479 1.354–1.616 <0.0001 1.425 1.237–1.643 <0.0001
Albuminuria category <0.0001 <0.0001
Normoalbuminuria 1.0 1.0
Microalbuminuria 1.646 1.498–1.809 <0.0001 2.046 1.803–2.323 <0.0001
Macroalbuminuiria 2.609 2.195–3.101 <0.0001 3.876 3.152–4.764 <0.0001
eGFR category <0.0001 <0.0001
90 ml/min/1.73 m2 1.0 1.0
60–89 ml/min/1.73 m2 0.977 0.884–1.080 0.650 1.095 0.948–1.265 0.219
30–59 ml/min/1.73 m2 1.229 1.078–1.400 0.002 1.529 1.278–1.830 <0.0001
<30 ml/min/1.73 m2 1.697 1.262–2.280 <0.0001 2.414 1.694–3.439 <0.0001
* Binary logistic regression analysis with backward conditional entering of independent variables.
DR = diabetic retinopathy; RIACE = Renal Insufficiency And Cardiovascular Events; OR = odd ratio; CI = confidence interval; TG = triglyceride;
RAS = renin-angiotensin system; eGFR = estimated glomerular filtration rate.
doi:10.1371/journal.pone.0125512.t004
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adding the quadratic term to the regression equation did not change significantly the results
(not shown).
Discussion
This study reports an association of hypertriglyceridemia with CKD, but not DR, in subjects
with type 2 diabetes. In these individuals, risk of CKD increased by 7–20% for every decile in-
crease in triglyceride concentrations. The relationship between triglycerides and CKD was
stronger with increasing severity of albuminuria, eGFR loss and CKD phenotype and was inde-
pendent of statin treatment. In fact, the burden of CKD was higher in HTG than in NTG indi-
viduals, with and without statins, though subjects on statins carried a higher risk than those
not treated with these agents (9–24% vs. 5–18% increase per decile). Excess risk was significant
for triglyceride values within the normal range in statin-treated patients.
These results are consistent with the literature, showing more frequently an association of
triglyceride levels with CKD than with DR [15–18]. They also confirm and extend the findings
Table 5. Odds ratios corresponding to a difference of one decile in triglycerides levels for measures of CKD in all subjects and in those without
and with statin treatment. *
Variable OR 95% CI P
All subjects
Microalbuminuria 1.062 1.046–1.079 <0.0001
Macroalbuminuria 1.181 1.146–1.217 <0.0001
eGFR 60–89 ml/min/1.73 m2 1.047 1.032–1.063 <0.0001
eGFR 30–59 ml/min/1.73 m2 1.151 1.125–1.178 <0.0001
eGFR <30 ml/min/1.73 m2 1.354 1.272–1.442 <0.0001
CKD Stages 1–2 1.068 1.051–1.085 <0.0001
CKD Stages >3 nonalbuminuric 1.110 1.086–1.136 <0.0001
CKD Stages >3 albuminuric 1.204 1.172–1.236 <0.0001
Subjects not on statin therapy
Microalbuminuria 1.050 1.028–1.071 <0.0001
Macroalbuminuria 1.169 1.122–1.218 <0.0001
eGFR 60–89 ml/min/1.73 m2 1.040 1.021–1.060 <0.0001
eGFR 30–59 ml/min/1.73 m2 1.142 1.107–1.179 <0.0001
eGFR <30 ml/min/1.73 m2 1.408 1.303–1.522 <0.0001
CKD Stages 1–2 1.046 1.023–1.069 <0.0001
CKD Stages >3 nonalbuminuric 1.088 1.055–1.122 <0.0001
CKD Stages >3 albuminuric 1.184 1.141–1.228 <0.0001
Subjects on statin therapy
Microalbuminuria 1.081 1.057–1.106 <0.0001
Macroalbuminuria 1.192 1.142–1.245 <0.0001
eGFR 60–89 ml/min/1.73 m2 1.064 1.041–1.088 <0.0001
eGFR 30–59 ml/min/1.73 m2 1.173 1.133–1.214 <0.0001
eGFR <30 ml/min/1.73 m2 1.315 1.197–1.444 <0.0001
CKD Stages 1–2 1.087 1.060–1.115 <0.0001
CKD Stages >3 nonalbuminuric 1.131 1.094–1.169 <0.0001
CKD Stages >3 albuminuric 1.242 1.198–1.288 <0.0001
* Binary logistic regression analysis with backward conditional entering of independent variables. Other covariates were age, male gender, smoking
status, diabetes duration, HbA1c, BMI, HDL and LDL cholesterol, hypertension, and blockade of the renin-angiotensin system.
doi:10.1371/journal.pone.0125512.t005
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of a recent multicenter cross-sectional case-control study, in which however CKD and DR
were variably defined and not graded [33]. Interestingly, this study reported that the OR for
CKD increased by 23% for every 0.5mmol/L (approximately 1 quintile) increase in triglycer-
ides, a figure quite similar to ours, whereas DR was significantly associated with triglycerides in
matched analysis but not after additional adjustment.
Our data are also in keeping with studies in experimental animals fed a high fat diet which
suggested that lipotoxicity might represent a major mechanism in renal disease by inducing
glomerulosclerosis and tubulo-interstitial injury, associated with renal lipid accumulation [34].
Deposition of triglycerides in renal parenchimal cells results from both increased glomerular
Fig 1. Adjusted risk of CKD Stages 1–2 (Panel A), CKD Stages 3–5 nonalbuminuric (Panel B) and CKD
Stages 3–5 albuminuric (Panel C) (OR [95%CI]) according to deciles of triglyceride levels in subjects
without (□) and with (●) statin treatment.ORs are adjusted for age, male gender, smoking status, diabetes
duration, HbA1c, BMI, HDL and LDL cholesterol, hypertension, and blockade of the renin-angiotensin system.
Significant at * P<0.0001, † P at least <0.01, ‡ P at least <0.05.
doi:10.1371/journal.pone.0125512.g001
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uptake of circulating lipids or tubular reabsorption of albumin-bound fatty acids [34] and en-
hanced renal fatty acid synthesis via a sterol regulatory element binding protein 1c-dependent
pathway [35]. Cellular lipids undergo chemical modification, particularly oxidation, with for-
mation of advanced lipoxidation endproducts, which exert injurious effect both directly and
via receptor-mediated pathways [36].
However, dyslipidaemia characterized by increased triglyceride levels, and to a lesser extent
reduced HDL cholesterol, is a known consequence of renal dysfunction, especially when eGFR
falls below 60 ml/min/1.73m2 [37], and is associated with adverse renal outcomes in CKD
Stages 3–5 [38]. This suggests that, in a cross-sectional analysis, the association between triglyc-
erides and CKDmight reflect the bidirectional nature of this relation. The finding of a signifi-
cant association between triglycerides and CKD, but not DR, seems to support this view.
However, this observation might also reflect the fact that lipid extravasation is restricted in the
retina by the blood-retinal barrier and that disruption of this barrier, rather than increased
lipid levels, is required for lipid-induced retinal injury [39]. Moreover, a significant relation be-
tween triglycerides and CKD was detected also for degrees of renal dysfunction which are not
accompanied by significant lipid abnormalities, such as CKD Stages 1–2 and eGFR 60–89 ml/
min/1.73m2. Yet, this relation was stronger with increasing severity of CKD, as defined by albu-
minuria and eGFR category or CKD phenotype, thus suggesting that it reflects also the impact
of impaired renal function on lipid profile.
Taken together, these data emphasize the role of triglycerides in the development of renal
disease associated with type 2 diabetes, though this relationship is bi-directional. In addition,
they suggest that statin therapy might be useful in diabetic subjects also by virtue of its ability
to reduce triglyceride levels. Results from our study and from that of Sacks et al [33] also sug-
gest that data from the Action to Control Cardiovascular Risk in Diabetes Lipid Trial and the
Fenofibrate Intervention and Event Lowering in Diabetes Study [19–21] should be revisited. In
fact, targeting triglycerides might be effective in preventing or delaying loss of renal function in
diabetic individuals beyond the stimulation of peroxisome proliferator-activated receptor-α in-
duced by fibrates, which might reduce renal lipid synthesis [34]. This view is supported by the
independent association between elevated triglyceride levels and measures of CKD, though
data from statin-treated patients do not allow to draw conclusive remarks. In fact, this associa-
tion was independent from statin treatment. Moreover, in a cross-sectional analysis, the higher
CKD risk in subjects with than in those without statin therapy within each triglyceride category
(NTG or HTG) or decile may raise different interpretations. On the one hand, it may indicate
that statin treatment is not very effective in reducing CKD risk in diabetic patients, as also sug-
gested by the observation that excess risk was significant for triglyceride values within the nor-
mal range in statin-treated subjects. Furthermore, it might reflect reverse causality, since CKD
is associated with dyslipidemia which requires statin treatment. On the other hand, the fact
that ORs for measures of CKD were lower in NTG subjects on statins than in HTG individuals
not on statins, might indicate that statin treatment is effective, since NTG patients on statins
likely had high triglycerides before starting statin therapy, in keeping with the observation that
the higher are triglyceride levels at baseline the higher is the extent of their reduction with stat-
ins [40].
Strengths of this study include the large size of the cohort, the completeness of data, the
analysis of a contemporary dataset, and particularly the standardized definition and grading of
microvascular complications and the dissection of the effect of statin treatment. The latter was
facilitated by the characteristics of the cohort, in which less than half of subjects were on statins
(and only a few on fibrates), as reported in other cohorts [23,41]. The main limitation is the
cross-sectional design of the study which did not allow to exclude reverse causality that might
have affected the analysis of the bi-directional relationship between triglyceride levels or statin
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treatment and CKD. Potential limitations concerning assessment of CKD and DR, including
non-centralized measurements of albuminuria and serum creatinine and the use of funduscopy
have been extensively addressed in previous RIACE reports [25,26,30,31].
In conclusion, this cross-sectional analysis of the large RIACE cohort showed that hypertri-
glyceridemia is associated with renal, but not retinal, complications in subjects with type 2 dia-
betes. This relationship was independent of statin treatment, which is known to decrease
triglyceride levels, and excess risk was observed for triglyceride values within the normal range
in statin-treated patients.
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